Bioneer Corporation
KKRX:0645507,470.00
KRW
-300.00
(-3.86%)
ISIN
KR7064550007
Return %
Stock
S&P 500
1Y
-44.91
14.20
3Y
-76.40
81.12
5Y
-86.22
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Han-Oh Park
- Full Time Employees
- 362
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 8-11, Munpyeongseo-ro Daejeon DE South Korea 34013
- IPO Date
- Dec 29, 2005
- Website
- bioneer.co.kr
- Similar Companies
- Business
- Bioneer Corporation operates as a biotechnology company specializing in the development, manufacturing, and distribution of molecular biology products and molecular diagnostics. Its core offerings include DNA and RNA amplification products such as PCR and real-time PCR reagents; nucleic acid purification kits; oligonucleotide synthesis products including siRNA libraries and custom oligos; enzymes including thermostable polymerases and reverse transcriptases; protein expression and purification reagents; DNA ladders and markers; and a range of molecular diagnostic kits and instruments. The company also provides gene synthesis services, fluorescence dyes and quenchers, electrophoresis equipment, magnetic separation services, and sample preparation tools. Additionally, Bioneer offers products for molecular diagnosis covering human, animal, aquatic bio, mosquito-borne, and plant diseases, as well as food safety and nano-bio sectors. Its instruments portfolio includes conventional PCR machines, real-time PCR systems, centrifuges, vortex mixers, and DNA sequencers. Bioneer serves diverse geographic markets including South Korea, the Americas, Europe, Asia, and Africa. Founded in 1992 and headquartered in Daejeon, South Korea, Bioneer is recognized as one of Korea’s leading biotechnology firms with comprehensive capabilities integrating recombinant DNA technology, fermentation, biochemistry, nucleic acid chemistry, mechanics, photonics, and electronics to develop next-generation bio-technologies. The company operates two production and research facilities in Korea totaling approximately 226,000 square feet. Recent developments at Bioneer include product innovations such as the launch of a novel auxiliary device called “AccuLoader™” aimed at improving reagent dispensation efficiency. The company also continues strategic expansion through research into synthetic biology, siRNA drug development, and cosmeceuticals, supported by a broad patent portfolio exceeding 600 global patents. Its founder and CEO, Han-Oh Park, was recently awarded the 2025 FACS Award for Distinguished Contribution to Economic Advancement, underscoring the company's ongoing commitment to innovation and global competitiveness. Bioneer's subsidiaries include AceBiome and siRNAgen Therapeutics, which support its diversification into microbiome research and RNA-based therapeutics. The company’s business segments encompass biotechnology research products, molecular diagnostics, drug development, and probiotics. Its target markets range from academic and clinical research institutions to pharmaceutical companies and diagnostic laboratories worldwide. Bioneer maintains a strong presence internationally, supporting global life sciences research and diagnostics with comprehensive genomic solutions. Bioneer Corporation is listed on the KOSDAQ stock exchange under the ticker 064550.KQ, employing around 377 personnel. It continues to focus on delivering integrated diagnostics and research tools globally, reinforcing its role as a strategic partner in life sciences and medical research industries.